GlassScriptPhysician profile
Staci M Sheba
NPI 1538133871
$17,236.80
in general payments reported to CMS, 2019-2025
61 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $2,512 · 2021: $2,953 · 2022: $2,751 · 2023: $2,798 · 2024: $3,126 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,369 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,368.66 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,978.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,453.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,394.34 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,329.87 | 2019-2025 | |
| Abbvie INC. | $1,310.74 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $1,098.78 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $932.60 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $863.05 | 2019-2024 | Xarelto |
| Amgen INC. | $663.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $544.53 | 2021-2025 | |
| Exact Sciences Corporation | $505.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $420.15 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $405.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $384.88 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $378.16 | 2020-2024 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Sheba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.